Explain this page
Arphra AIPlain-English read on Agree Realty Corporation’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Peers
No peer list available for ADC.
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.27% | -3.85% | -5.09% | -9.95% | -2.91% | +0.61% | -3.99% | +12.79% | +1.81% | +69.32% | +271.64% |
Aftermarket
LiveLast trade
$73.02
36 sh
Bid
$72.50
1 sh
Ask
$74.44
1 sh
Spread
$1.940
Sector & industry today
LiveSectors
- Technology+0.67%
- Basic Materials+0.15%
- Communication Services+0.13%
- Real Estate-0.13%
- Industrials-0.48%
- Energy-0.58%
- Healthcare-0.65%
- Financial Services-0.80%
- Consumer Defensive-0.85%
- Consumer Cyclical-0.85%
- Utilities-1.15%
Top industries (issuer's industry highlighted)
- REIT - Retail+0.15%
- Computer Hardware+8.35%
- Software - Infrastructure+7.61%
- Coal+5.76%
- Consulting Services+5.28%
- Medical - Healthcare Information Services+5.23%
- Medical - Diagnostics & Research+4.96%
- REIT - Healthcare Facilities-3.49%
- Broadcasting-3.48%
- Software - Application+3.44%
- Advertising Agencies+3.24%
- Biotechnology+3.22%
Fair value
Football field →Weighted blend
$49.56
-31.61% vs spot
Recommendation
Sell
4 of 4 methods
Method spread
0bull4bear
±5% threshold
Analyst PT consensus: $83.94 (+15.83%)
Total assets
$9.8B
Total debt
$3.35B
Cash & equiv
$16.3M
Operating CF
$504.14M
Free cash flow
$504.14M
Buybacks
-$3.74M
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Marketsglobenewswire.com·May 12, 2026
- Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Marketsglobenewswire.com·May 12, 2026
- InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in Chinaglobenewswire.com·May 06, 2026
- Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Programbusinesswire.com·May 06, 2026
- ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updatesprnewswire.com·May 04, 2026
- ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updatesprnewswire.com·May 04, 2026
- Agree Realty: Bigger Investments, Stronger Growth Amid Uncertainty Puts Them In A Different Leagueseekingalpha.com·May 01, 2026
- ADC Therapeutics Makes Grants to New Employees Under Inducement Planprnewswire.com·May 01, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $200.81M | $62.23M | $0.50 |
| Q4 Dec 2025 | $190.49M | $56.04M | $0.47 |
| Q3 Sep 2025 | $183.22M | $52.12M | $0.45 |
| Q2 Jun 2025 | $175.53M | $49.2M | $0.44 |
| Q1 Mar 2025 | $169.16M | $47M | $0.42 |
| Q4 Dec 2024 | $160.73M | $45.24M | $0.41 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $718.4M | $340.4M | $204.35M | $1.77 | +28.45% |
| FY 2024 | $617.1M | $302.24M | $189.2M | $1.78 | +30.66% |
| FY 2023 | $537.5M | $254.39M | $169.96M | $1.70 | +31.62% |
| FY 2022 | $429.81M | $218.09M | $152.44M | $1.83 | +35.47% |
| FY 2021 | $339.32M | $190.27M | $122.27M | $1.78 | +36.03% |